Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

This is first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer. DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, …

cancer
carcinoma
mtor inhibitor
clear cell renal cell carcinoma
everolimus
  • 16 views
  • 30 Jun, 2022
  • 10 locations
Magnesium Sulfate Versus Dexmedetomidine on Anesthesia Awakening.

pheochromocytoma). Despite these advantages in the use of these important adjuncts, there is a concern about the quality and awakening time of the patients who use them. The purpose of this trial is to compare the

Accepts healthy volunteers
  • 0 views
  • 11 Nov, 2021
  • 1 location
Diagnosis of Pheochromocytoma

The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often

myocardial infarction
dopa
adrenaline
positron emission tomography/computed tomography
MRI
  • 20 views
  • 28 Jul, 2022
  • 1 location
Multicenter Pheochromocytoma and Paraganglioma Evaluation

Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility

special care
paraganglioma
adrenal pheochromocytoma
pheochromocytoma
  • 36 views
  • 24 Jan, 2021
  • 1 location
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible …

metastatic disease
somatostatin
dotatate
  • 0 views
  • 15 Jul, 2022
  • 11 locations
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Pheochromocytoma/Paraganglioma.

stage iv adrenocortical cancer
malignant pheochromocytoma
metastatic disease
nivolumab
pheochromocytoma, malignant
  • 14 views
  • 17 Dec, 2021
  • 13 locations
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors (MK-6482-015)

This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET) or von

  • 0 views
  • 20 Jul, 2022
  • 39 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) Pheochromocytoma

extrahepatic cholangiocarcinoma
pheochromocytoma, malignant
ultrasound examination
oophorectomy
brain metastases
  • 6634 views
  • 10 Aug, 2022
  • 752 locations
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

Background People with von Hippel-Lindau (VHL) can have problems with a variety of organs, such as the pancreas. The disease can cause tumors of the pancreas. This can result in life-threatening complications. Researchers want to learn more about these pancreatic tumors and how to better detect them. This may help …

ct scan
cyst
genetic testing
dotatate
neuroendocrine tumor
  • 0 views
  • 29 Jul, 2022
  • 1 location
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001)

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

kidney function test
cancer
solid tumour
RET
systemic therapy
  • 1278 views
  • 10 Aug, 2022
  • 86 locations